1
|
Yang L, Ma Q, Chen J, Kong X, Yu X, Wang W. Foxa2 attenuates steatosis and inhibits the NF-κB/IKK signaling pathway in nonalcoholic fatty liver disease. PeerJ 2023; 11:e16466. [PMID: 38084145 PMCID: PMC10710773 DOI: 10.7717/peerj.16466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 10/24/2023] [Indexed: 12/18/2023] Open
Abstract
Objective Forkhead box a2 (Foxa2) is proven to be an insulin-sensitive transcriptional regulator and affects hepatic steatosis. This study aims to investigate the mechanism by which Foxa2 affects nonalcoholic fatty liver disease (NAFLD). Methods Animal and cellular models of NAFLD were constructed using high-fat diet (HFD) feeding and oleic acid (OA) stimulation, respectively. NAFLD mice received tail vein injections of either an overexpressing negative control (oe-NC) or Foxa2 (oe-Foxa2) for four weeks. HepG2 cells were transfected with oe-NC and oe-Foxa2 for 48 h before OA stimulation. Histological changes and lipid accumulation were assessed using hematoxylin-eosin staining and oil red O staining, respectively. Expression of Foxa2, NF-κB/IKK pathway proteins, lipid synthesis proteins, and fatty acid β-oxidation protein in HFD mice and OA-induced HepG2 cells was detected using western blot. Results Foxa2 expression was downregulated in HFD mice and OA-induced HepG2 cells. Foxa2 overexpression attenuated lipid accumulation and liver injury, and reduced the levels of aspartate aminotransferase, alanine aminotransferase, total cholesterol, or triglyceride in HFD mice and OA-induced HepG2 cells. Moreover, Foxa2 overexpression decreased the expression of lipid synthesis proteins and increased fatty acid β-oxidation protein expression in the liver tissues. Furthermore, overexpression of Foxa2 downregulated the expression of p-NF-κB/NF-κB and p-IKK/IKK in OA-induced HepG2 cells. Additionally, lipopolysaccharide (NF-κB/IKK pathway activator) administration reversed the downregulation of lipid synthesis proteins and the upregulation of fatty acid β-oxidation protein. Conclusion Foxa2 expression is downregulated in NAFLD. Foxa2 ameliorated hepatic steatosis and inhibited the activation of the NF-κB/IKK signaling pathway.
Collapse
Affiliation(s)
- Li Yang
- Northwest Minzu University, Lanzhou, Gansu, China
| | - Qiang Ma
- Department of Gastroenterology, 940th Hospital of Joint Support Force, Lanzhou, Gansu, China
| | - Jiayu Chen
- Department of Gastroenterology, 940th Hospital of Joint Support Force, Lanzhou, Gansu, China
| | - Xiangcai Kong
- Department of Gastroenterology, 940th Hospital of Joint Support Force, Lanzhou, Gansu, China
| | - Xiaohui Yu
- Department of Gastroenterology, 940th Hospital of Joint Support Force, Lanzhou, Gansu, China
| | - Wei Wang
- Department of Gastroenterology, 940th Hospital of Joint Support Force, Lanzhou, Gansu, China
| |
Collapse
|
2
|
Gao W, Du L, Li N, Li Y, Wu J, Zhang Z, Chen H. Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in hyperlipidemic rats by inhibiting inflammation, oxidative stress and NF-κB. Chem Biol Drug Des 2023; 102:1176-1185. [PMID: 37604597 DOI: 10.1111/cbdd.14324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 07/04/2023] [Accepted: 07/24/2023] [Indexed: 08/23/2023]
Abstract
The present study was conducted to determine the protective effect of Dexmedetomidine (DEX) in myocardial ischemia-reperfusion injury in hyperlipidemic rats. Towards this, the effect of DEX was first evaluated on the infarct size and the histopathology of cardiac tissues using TTC and H and E staining, and it was found that DEX significantly improved the infarct size and architecture of the myocardial tissues following the I/R injury. DEX also showed significant improvement in various examined hemodynamic parameters (e.g., LVSP, and ± dp/dtmax ) in a dose-dependent manner. The lipid profile (LDL, VLDL, TC, TG, and HDL level) of the rats were also found significantly improved in DEX-treated rats. The level of various pro-inflammatory cytokines (IL-1β, IL-6, IL-10, IL-17, and TNF-α), cardiac injury (CK, CK-MB, Troponin I AST, ALT, and LDH), and oxidative stress (MDA, SOD, and GSH) biomarkers were also found to be restored near to the normal in DEX-treated group. It has been found that DEX also significantly reduces apoptosis of rat cardiomyocytes. In western blot analysis, DEX showed a significant reduction in the activation of NF-κB. In conclusion, our study demonstrated the protective effect of Dexmedetomidine in myocardial ischemia-reperfusion injury in hyperlipidemic rats possibly via amelioration of oxidative stress, and inflammation apoptosis.
Collapse
Affiliation(s)
- Weiwei Gao
- Department of Anesthesiology, The First Hospital of Hebei Medical University, Shijiazhuang, China
| | - Liang Du
- Department of Anesthesiology, The First Hospital of Hebei Medical University, Shijiazhuang, China
| | - Nan Li
- Operating Center, The First Hospital of Hebei Medical University, Shijiazhuang, China
| | - Yating Li
- Pharmacy Intravenous Admixture Services, The First Hospital of Hebei Medical University, Shijiazhuang, China
| | - Jinfang Wu
- Operating Center, The First Hospital of Hebei Medical University, Shijiazhuang, China
| | - Ze Zhang
- Department of Anesthesiology, The First Hospital of Hebei Medical University, Shijiazhuang, China
| | - Huan Chen
- Department of Anesthesiology, The First Hospital of Hebei Medical University, Shijiazhuang, China
| |
Collapse
|
3
|
Zhu L, Zhang Y. Discovery of novel Ketamine-inspired derivatives as a protective agent against renal ischemic/reperfusion injury in Wistar rats. Chem Biol Drug Des 2021; 100:13-24. [PMID: 34923757 DOI: 10.1111/cbdd.14011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 11/20/2021] [Accepted: 12/09/2021] [Indexed: 11/28/2022]
Abstract
Renal ischemia-reperfusion (I/R) injury is a limiting factor for the success of renal grafts and is deemed greatly responsible for the mortality. A novel series of Ketamine inspired compounds were synthesized and subjected to NF-ĸB transcriptional inhibitory activity in LPS-stimulated RAW264.7 cells, where entire set of compounds showed mild to significant NF-ĸB transcriptional inhibitory activity (IC50 6.53 - 67.52 µM). Compound 6d showed highest inhibitory activity among the tested series (IC50 2.62 µM), and found more potent as compared to Ketamine as standard. The effect of compound 6d was further quantified in I/R injury in Wistar rats, where it dose-dependently improves kidney function of rats with significant amelioration of kidney injury as suggested by histopathological examination of renal tissues. It further showed reduction in the generation of pro-inflammatory cytokines and improves the anti-oxidant status of experimental rats. Compound 6d inhibited apoptosis and increases the expression of Bcl2 and decreases Bax, and cleaved caspase-3 level. It further reduces TLR-4 and NF-κB expression in renal cells of rats, with increases in IκB-α level in western blot analysis as compared to I/R group. In summary, our current study showed the development of a novel class of Ketamine-inspired derivatives against renal ischemia/reperfusion injury.
Collapse
Affiliation(s)
- Li Zhu
- Department of Surgical Anesthesiology, University-Town Hospital of Chongqing Medical University, Chongqing, China, 401331
| | - Yin Zhang
- Department of Surgical Anesthesiology, University-Town Hospital of Chongqing Medical University, Chongqing, China, 401331
| |
Collapse
|
4
|
Reid S, Scholey JW. Recent Approaches to Targeting Canonical NF κB Signaling in the Early Inflammatory Response to Renal IRI. J Am Soc Nephrol 2021; 32:2117-2124. [PMID: 34108233 PMCID: PMC8729839 DOI: 10.1681/asn.2021010069] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Accepted: 04/22/2021] [Indexed: 02/04/2023] Open
Abstract
Ischemia reperfusion injury (IRI) is the most common cause of in-hospital AKI and is associated with increased morbidity and mortality. IRI is associated with an early phase of inflammation primarily regulated by the canonical NFκB signaling pathway. Despite recent advances in our understanding of the pathogenesis of IRI, few therapeutic strategies have emerged. The purpose of this manuscript is to review interventions targeting NFκB after IRI.
Collapse
Affiliation(s)
- Shelby Reid
- Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada
| | - James W. Scholey
- Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada,Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada
| |
Collapse
|
5
|
Sun L, Zou LX, Han YC, Wu L, Chen T, Zhu DD, Hu P. A20 overexpression exerts protective effects on podocyte injury in lupus nephritis by downregulating UCH-L1. J Cell Physiol 2019; 234:16191-16204. [PMID: 30805933 DOI: 10.1002/jcp.28282] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 11/23/2018] [Accepted: 11/30/2018] [Indexed: 01/24/2023]
Abstract
Lupus nephritis (LN), an autoimmune kidney disease caused by systemic lupus erythematosus (SLE), is the inflammation of the kidney. Although the treatment of LN is still a therapeutic challenge for many practitioners, the present study aims to provide a new insight for the treatment and management. The study aims to explore the effect of A20 on LN in relation to the nuclear factor-kappa B (NF-κB) signaling pathway. MRL/lpr mice were used as the LN mouse model. Next, A20, UCH-L1, and NF-κB expression in LN patients and MRL/lpr mice was determined. A20 was upregulated in podocytes to assess biological functions of A20 in LN. Furthermore, to further investigate the pivotal role of the NF-κB pathway in LN, the NF-κB pathway was blocked in podocytes. Next, UCH-L1 was downregulated in MRL/lpr mice to assess biological functions of UCH-L1 in LN. A20 was downregulated, whereas UCH-L1 was upregulated in LN. Overexpressed A20 declined NF-κB, UCH-L1 expression, and the extent of p65 phosphorylation. A20 overexpression or UCH-L1 inhibition increased expression of synaptoporin and nephrin but decreased desmin expression and ubiquitin accumulation level in podocytes. Moreover, A20 overexpression or UCH-L1 inhibition increased the podocyte number but decreased protein level of cleaved caspase-3, podocyte lesion improvement, decreased foot process width, glomerulus basement membrane, and foot process fusion rate. In addition, urine protein, blood urea nitrogen, serum creatinine, and ds-DNA antibody levels decreased with elevated A20 or depleted UCH-L1. Collectively, it could be concluded that A20 protects against podocyte injury in LN via UCH-L1 by inactivating the NF-κB signaling pathway.
Collapse
Affiliation(s)
- Ling Sun
- Department of Nephrology, Xuzhou Central Hospital, Medical College of Southeast University, Xuzhou, Jiangsu, China
| | - Lu-Xi Zou
- School of Management, Zhejiang University, Hangzhou, China
| | - Yu-Chen Han
- Institute of Nephrology, Zhongda Hospital, Southeast University, China
| | - Ling Wu
- Department of Nephrology, Xuzhou Central Hospital, Medical College of Southeast University, Xuzhou, Jiangsu, China
| | - Ting Chen
- Department of Nephrology, Xuzhou Central Hospital, Medical College of Southeast University, Xuzhou, Jiangsu, China
| | - Dong-Dong Zhu
- Institute of Nephrology, Zhongda Hospital, Southeast University, China
| | - Po Hu
- Department of Nephrology, Xuzhou Central Hospital, Medical College of Southeast University, Xuzhou, Jiangsu, China
| |
Collapse
|
6
|
Abstract
The global burden of chronic kidney disease will increase during the next century. As NFκB, first described more than 30 years ago, plays a major role in immune and non-immune-mediated diseases and in inflammatory and metabolic disorders, this review article summarizes current knowledge on the role of NFκB in in vivo kidney injury and describes the new and so far not completely understood crosstalk between canonical and non-canonical NFκB pathways in T-lymphocyte activation in renal disease.
Collapse
Affiliation(s)
- Ning Song
- III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Friedrich Thaiss
- III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Linlin Guo
- III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
7
|
Qiu Y, Wu Y, Zhao H, Sun H, Gao S. Maresin 1 mitigates renal ischemia/reperfusion injury in mice via inhibition of the TLR4/MAPK/NF-κB pathways and activation of the Nrf2 pathway. Drug Des Devel Ther 2019; 13:739-745. [PMID: 30863013 PMCID: PMC6388965 DOI: 10.2147/dddt.s188654] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Inflammation and oxidative stress play a crucial role in the pathogenesis of renal ischemia/reperfusion injury (IRI). Maresin 1 (MaR1), which has shown strong anti-inflammatory and antioxidant effects, was recently reported to have protective properties in several different animal models. AIM The objectives of our study were to determine whether MaR1 alleviates renal IRI and to identify the underlying mechanisms. MATERIALS AND METHODS The mouse model in this study was induced by ischemia of the left kidney for 45 minutes and by nephrectomy of the right kidney. All mice were intravenously injected with a vehicle or MaR1. Renal histopathologic changes, function, proinflammatory cytokines, and oxidative stress were assessed. The expression of proteins was measured by Western blot. RESULTS The results indicated that MaR1 markedly protected against renal IRI. The protective effects were accompanied by the reduction of histologic changes and reduction of renal dysfunction. Meanwhile, MaR1 remarkably mitigated renal IRI-induced inflammation and oxidative stress. In addition, our results showed that MaR1 significantly inhibited the expression of TLR4 and the expression of phosphorylated Erk, JNK, and P38. Furthermore, MaR1 decreased the nuclear translocation of NF-κB and increased the nuclear translocation of Nrf2. CONCLUSION MaR1 protects against renal IRI by inhibiting the TLR4/MAPK/NF-κB pathways, which mediate anti-inflammation, and by activating the Nrf2 pathway, which mediates antioxidation.
Collapse
Affiliation(s)
- Yun Qiu
- Department of Emergency Medicine, The Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu Province, China,
| | - Yichen Wu
- Department of Emergency Medicine, The Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu Province, China,
| | - Hongmei Zhao
- Department of Emergency Medicine, The Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu Province, China,
| | - Hong Sun
- Department of Emergency Medicine, The Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu Province, China,
| | - Sumin Gao
- Department of Emergency Medicine, The Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu Province, China,
| |
Collapse
|
8
|
Yamashita M, Yoshida T, Hayashi M. Podocyte NF-κB is dispensable for the pathogenesis of renal ischemia-reperfusion injury. Physiol Rep 2017; 4:4/16/e12912. [PMID: 27565904 PMCID: PMC5002916 DOI: 10.14814/phy2.12912] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 08/01/2016] [Indexed: 11/24/2022] Open
Abstract
Podocytes play a central role in the formation of the glomerular filtration barrier in the kidney, and their dysfunction has been shown to result in multiple proteinuric kidney diseases. In this study, we sought to determine whether NF-κB, a proinflammatory signaling, within podocytes was involved in renal ischemia-reperfusion (I/R) injury. Podocyte-specific IκBΔN transgenic (Pod-IκBΔN) mice, in which NF-κB was inhibited specifically in podocytes, were generated by the Cre-loxP technology, and their phenotype was compared with control mice after bilateral renal ischemia. The effect of systemic administration of a NF-κB inhibitor, pyrrolidinedithiocarbamate (PDTC), on renal I/R injury was also examined. Pod-IκBΔN mice were phenotypically normal before surgery. Following renal I/R injury, serum concentrations of urea nitrogen and creatinine were elevated in both Pod-IκBΔN and control mice to a similar extent, whereas PDTC treatment attenuated the elevation of these parameters. Renal histological damage in I/R-injured Pod-IκBΔN mice was also similar to I/R-injured control mice, although it was improved by PDTC treatment. Moreover, I/R induced accumulation of inflammatory cells, such as neutrophils and macrophages, was reduced by PDTC treatment, but not by podocyte-specific NF-κB inhibition. These results provide evidence that the NF-κB activity in podocytes does not contribute to the pathogenesis of renal I/R injury.
Collapse
Affiliation(s)
- Maho Yamashita
- Apheresis and Dialysis Center, School of Medicine, Keio University, Tokyo, Japan
| | - Tadashi Yoshida
- Apheresis and Dialysis Center, School of Medicine, Keio University, Tokyo, Japan Department of General Medicine, School of Medicine, Keio University, Tokyo, Japan
| | - Matsuhiko Hayashi
- Apheresis and Dialysis Center, School of Medicine, Keio University, Tokyo, Japan Department of General Medicine, School of Medicine, Keio University, Tokyo, Japan
| |
Collapse
|